(Rac)-JBJ-04-125-02

CAS No. 2140807-05-0

(Rac)-JBJ-04-125-02 ( —— )

Catalog No. M23974 CAS No. 2140807-05-0

JBJ-04-125-02 is effective as a single agent in both in vitro and in vivo models of EGFR-mutant lung cancer.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 205 In Stock
10MG 335 In Stock
25MG 566 In Stock
50MG 806 In Stock
100MG 1098 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    (Rac)-JBJ-04-125-02
  • Note
    Research use only, not for human use.
  • Brief Description
    JBJ-04-125-02 is effective as a single agent in both in vitro and in vivo models of EGFR-mutant lung cancer.
  • Description
    JBJ-04-125-02 is effective as a single agent in both in vitro and in vivo models of EGFR-mutant lung cancer.
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    EGFR (L858R/T790M )
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2140807-05-0
  • Formula Weight
    543.6
  • Molecular Formula
    C29H26FN5O3S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:240mg/mL (441.5 mM);Water:Insoluble
  • SMILES
    C1CN(CCN1)C2=CC=C(C=C2)C3=CC4=C(CN(C4=O)C(C5=C(C=CC(=C5)F)O)C(=O)NC6=NC=CS6)C=C3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor
molnova catalog
related products
  • Theliatinib

    Theliatinib a potent and highly selective EGFR inhibitor with anti-tumor activity. Ki of 0.05 nM for wild type EGFR and IC50s of 3 and 22 nM for EGFR and EGFR T790M/L858R mutant respectively.

  • Nimotuzumab

    Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).

  • TX1-85-1

    TX1-85-1 induces partial degradation of Her3 protein and attenuates Her3-dependent signaling.